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The molecular mechanisms that control the balance between antiangiogenic and proangiogenic factors and 
initiate the angiogenic switch in tumors remain poorly defined. By combining chemical genetics with mul-
timodal imaging, we have identified an autocrine feed-forward loop in tumor cells in which tumor-derived 
VEGF stimulates VEGF production via VEGFR2-dependent activation of mTOR, substantially amplifying the 
initial proangiogenic signal. Disruption of this feed-forward loop by chemical perturbation or knockdown of 
VEGFR2 in tumor cells dramatically inhibited production of VEGF in vitro and in vivo. This disruption was 
sufficient to prevent tumor growth in vivo. In patients with lung cancer, we found that this VEGF:VEGFR2 
feed-forward loop was active, as the level of VEGF/VEGFR2 binding in tumor cells was highly correlated to 
tumor angiogenesis. We further demonstrated that inhibition of tumor cell VEGFR2 induces feedback activa-
tion of the IRS/MAPK signaling cascade. Most strikingly, combined pharmacological inhibition of VEGFR2 
(ZD6474) and MEK (PD0325901) in tumor cells resulted in dramatic tumor shrinkage, whereas monotherapy 
only modestly slowed tumor growth. Thus, a tumor cell-autonomous VEGF:VEGFR2 feed-forward loop pro-
vides signal amplification required for the establishment of fully angiogenic tumors in lung cancer. Inter-
rupting this feed-forward loop switches tumor cells from an angiogenic to a proliferative phenotype that 
sensitizes tumor cells to MAPK inhibition.
Introduction
Several receptor tyrosine kinases, such as VEGFR2, Flt1/
VEGFR1, VEGFR3, or PDGFR, have been implicated in tumor 
angiogenesis. When activated through binding of the respective 
ligand, they regulate related, yet distinct, processes involved in 
neoangiogenesis. Endothelial cell survival, migration, and prolif-
eration of blood vessels is regulated primarily by VEGF-A bind-
ing to VEGFR2 (1). In the canonical model, tumor cells express 
VEGF, which binds to VEGFR2 on endothelial cells (2), thus 
stimulating tumor vessel formation. This change from prevascu-
lar hyperplasia to highly vascularized tumors has been referred to 
as the angiogenic switch (1). In recent years, several studies have 
reported expression of VEGFR1 as well as VEGFR2 on tumor 
cells (3–5). An intriguing finding related to tumor cell expression 
of Flt1 was the observation that VEGF secreted by tumor cells 
triggers tumor cell proliferation by binding Flt1 (6). Moreover, 
in patients with lung cancer, an increase in VEGFR2 gene copy 
number is associated with chemoresistance and shorter survival 
(7). Here, we have sought to analyze the impact of VEGFR2 inhi-
bition on tumor cells by combining genetically controlled phar-
macological perturbations with multimodal PET imaging.
Results
VEGFR2 is differentially expressed on non-small-cell lung cancer – 
VEGFR2 inhibition alters amino acid transport in tumor cells but does 
not affect tumor cell proliferation. We used the human lung can-
cer cell lines H441 and H1975, which each expressed high levels 
of VEGFR2 (Figure 1A and Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI65385DS1). We treated mice engrafted with these 2 cell lines 
with the dual VEGFR2/EGFR inhibitor ZD6474, which has a 
40-fold lower activity against VEGFR1 (8). Both cell lines are resis-
tant to EGFR inhibition, due either to a KRAS mutation (H441) 
or to the presence of the T790M gatekeeper mutation of EGFR 
(H1975) (ref. 9 and Supplemental Figure 1B). Thus, any thera-
peutic impact on subcutaneous tumor growth of these cell lines 
is primarily due to VEGFR2 inhibition and cannot be attributed 
to inhibition of EGFR. In established tumors, ZD6474 treatment 
completely abolished methionine uptake after 7 days of treat-
ment, as determined by methyl-l-[11C]-methionine ([11C]MET) 
PET (Figure 1B and Supplemental Figure 1C). By contrast, uptake 
of 3′-deoxy-3′-[18F]-fluoro-l-thymidine ([18F]FLT), a marker of 
proliferation (10), was slightly increased (Figure 1B and Supple-
mental Figure 1C), suggesting that the cells continued to progress 
through the cell cycle. Thus, VEGFR2 inhibition seems to inhibit a 
VEGFR2-dependent signaling pathway in tumor cells that affects 
amino acid transport without affecting cellular proliferation 
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(Figure 1B). To investigate whether the reduction in [11C]MET 
uptake is specifically due to ZD6474-mediated VEGFR2 inhibi-
tion, we used a chemical genetic approach, which introduces a 
gatekeeper resistant mutation against ZD6474-induced VEGFR2 
inhibition. The substitution of Val916 to Met at the gatekeeper 
position of VEGFR2 creates a steric clash with the inhibitor that 
specifically prevents ZD6474 from binding to VEGFR2 (Figure 1C 
and ref. 11). The introduction of this resistant gatekeeper muta-
tion was sufficient to abrogate the inhibitory effect of ZD6474 on 
[11C]MET uptake (Supplemental Figure 1D). The cellular uptake 
of methionine is facilitated by the LAT1 transporter that is regu-
lated by mTOR (12). Hence, we hypothesized that VEGF-bound 
VEGFR2 on tumor cells induces a VEGFR2 signaling pathway via 
mTOR. Moreover, as VEGF secretion is regulated by mTOR, we 
sought to investigate whether VEGF/VEGFR2 signaling induces a 
feed-forward loop via mTOR.
VEGF/VEGFR2 signaling induces a feed-forward loop that is mediated 
by a VEGFR2/PI3K/mTOR/VEGF signaling cascade. Consistent with 
a feed-forward loop stimulating VEGF secretion in a VEGFR2-de-
pendent fashion, VEGF secretion was strongly induced by addi-
tion of exogenous VEGF in the VEGFR2-expressing tumor cell 
lines H1975, H441, and HCC1359 (Figure 1D and Supplemental 
Figure 2B), and this induction was blunted by treatment of cells 
with the VEGFR2 inhibitor ZD6474 (Figure 1D and Supplemental 
Figure 2B). To validate the specificity of VEGFR2 as the relevant 
target for inhibition of VEGFR2-dependent VEGF secretion, we 
used the gatekeeper resistant mutation against ZD6474-induced 
VEGFR2 inhibition (V916M) (Figure 1C). Introducing this muta-
tion in H1975 cells was sufficient to abrogate the ZD6474-in-
duced inhibition of VEGF secretion (Figure 1E). Under hypoxic 
conditions, induction of VEGF secretion was similarly inhibited 
by VEGFR2 inhibition (Supplemental Figure 3C), suggesting that 
this autocrine loop is also active in the physiological response to 
hypoxia. Rapamycin treatment similarly blunted VEGF-induced 
VEGF secretion of tumor cells, supporting the hypothesis that 
VEGFR2-dependent secretion of VEGF is under the control of 
mTOR (13), which also regulates methionine uptake via the LAT-1 
transporter (ref. 14 and Figure 1D). Moreover, VEGF-mediated 
stimulation of VEGFR2 induced S6 phosphorylation in tumor 
cells expressing high levels of VEGFR2 (Figure 1F, Supplemental 
Figure 2A, and Supplemental Figure 3A). Phosphorylation of S6 
coincided with the activation of PDK1, which might provide an 
alternative route for mTOR activation (Supplemental Figure 2A 
and ref. 15). In accordance with the induction of PI3K/mTOR/
VEGF signaling, PI3K inhibition resulted in reduced VEGF secre-
tion (Supplemental Figure 2B). We next formulated a general 
mathematical model describing the postulated VEGF:VEGFR2 
feed-forward mechanism. We then demonstrated that the behav-
ior of the model was consistent with the experimental results 
obtained (Supplemental Figure 4 and Supplemental Note).
Additionally, we detected a consistent reduction in phosphory-
lation of ERK and of AKT in H1975, H441, and HCC1359 cells 
(Figure 1F and Supplemental Figure 3A). Thus, in the setting of 
autocrine VEGF/VEGFR2 signaling, the slight reduction in tumor 
growth observed in response to VEGFR2 inhibition is likely to be 
independent of ERK-mediated proliferation. These results agree 
with those of our PET experiments, showing a continuous uptake 
of [18F]FLT (Figure 1B). Finally, we confirmed that the observed 
ZD6474-mediated effects were due to inhibition of VEGFR2 in 
tumor cells by ectopically expressing the ZD6474-resistant mutant 
of VEGFR2 (V916M) in H1975 cells (Figure 1, E and G, and ref. 
11). This mutant abolished ZD6474-mediated VEGFR2 dephos-
phorylation and activation of mTOR (Figure 1G). Most strikingly, 
this VEGFR2 gatekeeper mutant against ZD6474 was sufficient 
to rescue the tumor growth–inhibiting effects of ZD6474 in vivo 
(Figure 1H). Thus, in concordance with the [11C]MET PET data, 
the ZD6474-mediated effects on tumor VEGF/VEGFR2/mTOR 
signaling are predominantly due to inhibition of VEGFR2 on the 
tumor cells and not due to inhibition of other kinases or VEGFR2 
on endothelial cells.
We next sought to validate our findings on inhibition of VEGF/
VEGFR2/mTOR signaling with an additional VEGFR2 inhibitor, 
PTK787. As with ZD6474, treatment with PTK787 inhibited phos-
phorylation of S6 and reduced the level of secreted VEGF (Supple-
mental Figure 2, A and B). Further, we found that, in the absence 
of VEGF, ZD6474 had only a little effect on the activation on ERK 
and S6 kinase (Supplemental Figure 3E).
VEGF/VEGFR2 signaling is needed for the induction of tumor angio-
genesis and tumor formation in vivo. To validate our finding with 
an alternative approach, we stably silenced VEGFR2 with len-
tiviral shRNA in H1975 and H441 non-small-cell lung cancer 
(NSCLC) cells (Figure 2A and Supplemental Figure 5B). Consis-
tent with the [18F]FLT PET data, selective silencing of VEGFR2 
by shRNA did not reduce tumor cell proliferation in vitro (Sup-
plemental Figure 5A). By contrast, silencing of VEGFR2 dramat-
ically reduced secretion of VEGF by tumor cells in response to 
hypoxia (Figure 2B), thereby confirming that binding of VEGF 
to VEGFR2 amplifies VEGF secretion in a VEGFR2-dependent 
manner. Most strikingly, knockdown of VEGFR2 in tumor 
cells alone was sufficient to almost entirely abolish initiation 
of tumor growth in vivo (Figure 2C and Supplemental Figure 
5B), suggesting that autocrine VEGF/VEGFR2 signaling in 
tumor cells is required for the establishment of tumors in vivo. 
While the large tumors transduced with empty control vector 
(H1975eV tumors) exhibited a highly angiogenic phenotype with 
many CD31-positive blood vessels, the small residual tumors 
in which VEGFR2 had been stably silenced (H1975VEGFR2KD 
tumors) almost completely lacked blood vessels (Figure 2D). In 
concordance with the tissue culture results, these tumors lacked 
expression of VEGF, while H1975eV tumors expressed high 
amounts of VEGF (Figure 2D). Using bevacizumab (Avastin), we 
specifically stained for (human) tumor cell-derived VEGF. We 
herewith could demonstrate that silencing VEGFR2 on tumor 
cells dramatically reduced the secretion of tumor cell-derived 
VEGF (Figure 2D). We next analyzed whether the raised levels 
of VEGF in the VEGFR2 WT cells were due to elevated hypoxia. 
HIF-1α was equally expressed in wild-type (H1975WT), H1975eV, 
and H1975VEGFR2KD tumors (Supplemental Figure 5C). By stain-
ing with an antibody that specifically recognizes human VEGF 
bound to human VEGFR2, we confirmed that tumor cell-de-
rived VEGF binds to VEGFR2 on tumor cells in H1975eV tumors 
but to a much lesser degree in H1975VEGFR2KD xenograft tumors 
(16), supporting the presence of an autocrine loop in vivo 
(Figure 2D). Furthermore, H1975VEGFR2KD tumors had a mark-
edly reduced uptake of [15O]H2O, a measure of tumor blood 
flow as a functional readout of angiogenesis (17), when com-
pared with that of H1975eV tumors (Supplemental Figure 5D). 
As an alternative approach to determine whether VEGFR2 inhi-
bition on tumor cells can prevent tumor formation, we treated 
mice with the VEGFR2 inhibitor ZD6474 immediately after 
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Figure 1
A VEGF:VEGFR2 feed-forward loop in tumor cells boosts VEGF secretion. (A) VEGFR2 expression data from the 53 NSCLC cell lines were 
obtained using Affymetrix U133A arrays (21). (B) Mice with established tumors (H1975) were treated with ZD6474, and PET imaging was per-
formed on day 0 (before start of therapy) and at the indicated time points after treatment (left panels, [18F]FLT-PET; right panels, [11C]MET-PET). 
(C) Substitution of Val916 by Met at the gatekeeper position of VEGFR2 creates a steric clash with the inhibitor and prevents ZD6474 from binding. 
(D) Secretion of VEGF by H1975, H441, and (E) H1975 mutant cells (VEGFR2V916M) was determined in vitro by ELISA (D) following stimulation 
with increasing amounts of recombinant VEGF. H1975 and H441 cells were stimulated with the indicated concentrations of VEGF (V) and pre-
treated with the indicated compounds (ZD6474 [Z], 1 μM; rapamycin [R], 100 nM). (F and G) Cells were treated with VEGF and the indicated dose 
of ZD6474, and phosphorylation of VEGFR2 was determined by immunoprecipitation. (F) The impact on activation of downstream signaling was 
determined by immunoblotting. (H) H1975 mutant cells (VEGFR2V916M) or the wild-type control cells were injected into nude mice and treated with 
ZD6474 or vehicle on day 1 after tumor cell injections.
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tumor cell inoculation. In concordance with the results obtained 
with VEGFR2-knockdown cells, concomitant VEGFR2 inhibition 
in NSCLC-H1975 tumors expressing high levels of VEGFR2 com-
pletely abrogated the establishment of tumors in vivo (Figure 1H), 
paralleled by a strong reduction in tumor vessel density (Supple-
mental Figure 5F). This blocking of tumor growth can be attrib-
uted to inhibition of VEGFR2, as the introduction of the resistance 
mutation VEGFR2V916M in the H1975 cells was sufficient to abro-
gate the ZD6474-mediated treatment effect (Figure 1H). In con-
trast, tumor cells with low levels of VEGFR2 expression, such as 
H1650 and A549, were unaffected by concomitant VEGFR2 inhi-
bition (Supplemental Figure 5E). In the same manner, treatment 
of mice with bevacizumab at the same time of tumor cell inocula-
tion abrogated the establishment of tumors in vivo (Figure 2E). 
In summary, the VEGF:VEGFR2 feed-forward loop is active 
in tumor cells expressing high levels of VEGFR2 in vivo and is 
required for the establishment of fully angiogenic tumors, and its 
disruption (either by VEGFR2 inhibition or blockade of VEGF) is 
sufficient to completely prevent tumor formation in vivo.
VEGF:VEGFR2 feed-forward loop is active in primary human lung ade-
nocarcinomas. We next performed immunohistochemical analysis 
of VEGF and VEGFR2 in 117 surgically resected primary human 
lung adenocarcinomas (Figure 3A), revealing that VEGF expression 
correlated significantly with expression of VEGFR2 on the same 
tumor cells (P = 2.612 × 10–5) as well as with microvessel density 
(P = 2.2 × 10–11; Table 1 and Supplemental Figure 6). This indicates 
that activation of the autocrine VEGF/VEGFR2 signaling loop is a 
feature of highly angiogenic lung adenocarcinomas. Finally, stain-
ing of representative tumors with an antibody specifically recogniz-
ing VEGF bound to VEGFR2 confirmed that, in the tumors with 
coexpression of VEGF and VEGFR2, VEGF was indeed bound to 
VEGFR2 on tumor cells (Figure 3B). Moreover, adenocarcinomas 
Figure 2
Requirement of autocrine VEGF/VEGFR2 
signaling for induction of angiogenesis 
and tumor formation in vivo. (A) H1975 
cells (WT cells) were stably transduced 
with lentiviral shRNA vectors targeting 
VEGFR2 (shVEGFR2) or with empty 
vector control (eV). Knockdown efficiency 
was determined by Western blotting (top 
panel, Flt1; bottom panel, VEGFR2). (B) 
Stable cell lines were cultured over time 
and quantified under normoxic conditions 
or exposed to hypoxia (1% O2). VEGF 
secretion was determined over time by 
ELISA. (C) Stable cell lines were injected 
into nude mice, and tumor growth was 
monitored over time. (D) Tumors were 
harvested and stained for pan VEGF, 
CD31, human VEGF (using GFP-labeled 
Avastin), human VEGF complexed with 
VEGFR2, Ki67, pERK, and an antibody 
binding VEGF to VEGFR2. (E) H1975 
cells were injected into nude mice and 
treated with Avastin or vehicle on day 
1 and day 10 after tumor cell injections. 
Scale bar: 50 μm (VEGF, human VEGF); 
100 μm (pERK); 200 μm (CD31, Ki67, 
VEGF:VEGFR2).
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that exhibited coexpression and autocrine binding of VEGF and 
VEGFR2 presented a highly angiogenic phenotype (Figure 3B). 
These results support a critical function for the VEGF:VEGFR2 
feed-forward loop in primary lung tumors in patients.
Inhibition of VEGFR2 induces ERK signaling and sensitizes to MAPK 
inhibition. To our surprise, we found that H1975VEGFR2KD tumors 
exhibited increased levels of Ki67- and pERK-positive cells com-
pared with H1975eV tumors (Figure 2D). In the same manner, 
VEGF stimulation in vitro reduced pERK signaling that was again 
increased upon ZD6474 treatment (Figure 1F and Supplemen-
tal Figure 3A). Consistent with the in vitro data presented above, 
ZD6474 treatment induced inhibition of pS6 and an increase in 
pERK in vivo (Supplemental Figure 7E). We thus hypothesized that 
inhibiting the VEGF:VEGFR2 feed-forward loop results in activa-
tion of the ERK signaling pathway and thereby appears to induce a 
ERK-dependant proliferative phenotype. Recently, Rosen and col-
leagues described a negative feedback regulation of IGF signaling 
via mTOR and its transcriptional regulation of FOXO transcription 
factors (18). In line with these findings, we observed that inhibiting 
the VEGF/VEGFR2/mTOR autocrine feed-forward loop enhanced 
ERK signaling, as a result of activation of the insulin growth fac-
tor receptor (IGFR) signaling pathway via IRS-1 (Figure 4, C and 
D). This activation of ERK was mediated by increased FOXO lev-
els upon inhibition of VEGFR2/mTOR signaling (Figure 4D). 
Remarkably, combined inhibition of ERK signaling by PD0325901 
and VEGFR2 resulted in a dramatic reduction of tumor cell pro-
liferation, as indicated by [18F]FLT PET data, and, finally, in com-
plete tumor shrinkage in vivo (Figure 4, A and B, and Supplemen-
tal Figure 7, A and B). In order to confirm our findings on tumor 
response after combined PD0325901 and ZD6474 treatment in an 
orthotopic tumor model, we applied a murine Ras-mutated lung 
cancer model expressing VEGFR2 on tumor cells (Figure 5 and 
Supplemental Figure 7H). In accordance with our xenograft data, 
combined PD0325901 and ZD6474 treatment resulted in sub-
stantial tumor regression, as detected by bioluminescence imaging 
(BLI) (Figure 5). These findings support the hypothesis of a recent 
study that combined MEK and VEGFR inhibition enhances inhibi-
tion of tumor growth (19). Of note, complete tumor shrinkage was 
associated with the expression levels of VEGFR2 on tumor cells. In 
line with our hypothesis, NSCLC-H1650 and A549, which express 
only low levels of VEGFR2, did not respond to combined ZD6474 
and PD0325901 treatment (Supplemental Figure 7, C and D).
Discussion
We have identified a VEGF:VEGFR2 feed-forward loop in NSCLC 
cells expressing VEGFR2 that leads to a signal amplification and a 
boost in VEGF secretion, which is required for establishment of fully 
angiogenic tumors in vivo. This VEGF/VEGFR2 signaling cascade 
via VEGFR2/PI3K/mTOR induces a mTOR-dependent regulation of 
VEGF secretion (13). VEGF secretion is induced by the upregulation 
of HIF-1α, which has been shown to be specific to mTORC1 and 
unaffected by the status of mTORC2 (20). This is supported by our 
observation that mTORC1 inhibition with rapamycin can prevent 
elevated VEGF expression induced by the feed-forward loop. Treat-
ment with Torin1, an inhibitor of TORC1 and TORC2, did not 
further reduce VEGF levels in comparison to rapamycin (Supple-
mental Figure 2B). Thus, our data strongly support that VEGFR2/
mTOR-induced VEGF secretion is mediated via mTORC1.
Figure 3
The VEGF:VEGFR2 feed-forward loop in primary 
human lung adenocarcinomas. (A) Human ade-
nocarcinomas were immunofluorescently stained 
to reveal coexpression of VEGF and VEGFR2 
by the same tumor cell population. Scale bar: 
50 μm. (B) A representative patient (Pat 1) with 
an high angiogenic phenotype represented by 
high VEGF:VEGFR2 staining and high levels of 
CD31-positive cells. In contrast, another patient 
(Pat 2) presents a low angiogenic phenotype, 
with only moderate levels of VEGF:VEGFR2–
positive tumor cells, corresponding to a low den-
sity of CD31-positive cells. Scale bar: 100 μm 
(top panels); 200 μm (bottom panels).
Table 1
Tissue microarrays of 117 lung adenocarcinomas
Intensity 0 1 2 3
VEGFR2 intensityA    
VEGF intensity 0 0 1 0 1
VEGF intensity 1 0 11 8 1
VEGF intensity 2 0 10 42 16
VEGF intensity 3 0 0 13 10
CD31 intensityB
VEGF intensity 0 0 0 2 0
VEGF intensity 1 0 17 3 0
VEGF intensity 2 0 13 52 3
VEGF intensity 3 0 3 9 11
VEGFR2 intensityC
CD31 intensity 0 0 0 0 0
CD31 intensity 1 0 11 19 3
CD31 intensity 2 0 11 35 20
CD31 intensity 3 0 0 9 5
Tissue microarrays of 117 lung adenocarcinomas were stained with 
antibodies recognizing human VEGFR2, VEGF, and CD31. Association 
of staining intensity, scored on a 0–3 scale, of the different antibodies 
in the same cohort is given in χ2 tables. Levels of significance were 
determined using Fisher’s exact test. AP = 2.612 × 10–5; BP = 2.2 × 10–11; 
CP = 0.01512.
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Our study supports a model wherein tumor cell-autonomous 
autocrine VEGF signaling loops form an integral part of the early 
phase of tumor development, promoting blood supply through 
angiogenesis. Consistent with this notion, we hypothesize that 
tumor cells reduce the proliferation in a VEGF/VEGFR2–depen-
dent manner as long as the nutrient supply remains decreased. 
This hypothesis is confirmed by our finding that inhibition of 
VEGFR2/mTOR signaling results in a time-dependent feed-
back activation of IRS/MAPK signaling (18). Interrupting the 
VEGF:VEGFR2 feed-forward loop induces a therapeutically 
relevant dependency on MAPK signaling in vivo. As a conse-
quence, combined inhibition of VEGFR2 and ERK signaling 
results in substantial tumor shrinkage in tumors in which this 
VEGF:VEGFR2 feed-forward loop is active. Our findings pro-
vide a potential mechanism for synergistic treatment effects of 
combined VEGFR2 and MAPK inhibition by PD0325901 and 
ZD6474. Finally, we have found that about 20% of patients with 
lung cancer show high tumor cell VEGFR2 expression, which 
correlates with a highly angiogenic phenotype. We therefore 
propose that high expression of VEGF:VEGFR2 on tumor cells 
could serve as a predictive marker for therapeutic efficacy of dual 
VEGFR2/MEK inhibition in patients with lung cancer. In sum-
mary, this study demonstrates the existence of a novel autocrine 
VEGF/VEGFR2 signaling loop, which amplifies VEGF secretion 
by tumor cells and is required to provide a switch for development 
of fully angiogenic tumors in vivo.
Methods
VEGFR2 expression in NSCLC cell lines. VEGFR2 expression data for the 53 
NSCLC cell lines were obtained using Affymetrix U133A arrays (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14925). RNA extrac-
tion, hybridization, and scanning of arrays were performed using stan-
dard procedures. CEL files from U133A arrays were preprocessed as 
described previously (21).
Cell lines and reagents. NSCLC cell lines, H441, H1975, A549, and H1650, 
were maintained in RPMI medium with 10% FCS and 1% (penicillin plus 
streptomycin) antibiotic. VEGF was purchased from Tebu-bio GmbH, 
ZD6474 was purchased from AstraZeneca, rapamycin was purchased 
from LC Labs, Torin 1 was purchased from Tocris Bioscience, and PK90 
was purchased from Axon Medchem. Compound stocks were stored at 
–20°C and dissolved in DMSO or vehicle solution in a rotating device at 
4°C for animal therapy.
Figure 4
Combined inhibition of VEGFR2 
and ERK signaling results in dra-
matic tumor shrinkage. (A) H1975 
cells were engrafted subcuta-
neously in nude mice; mice with 
established tumors were treated 
with a combination of ZD6474 plus 
PD0325901, and [18F]FLT-PET 
imaging was performed on day 0 
(before treatment) and at the indi-
cated time points after treatment. 
Representative imaging results are 
shown. ID, injected dose. (B) Tumor 
size of subcutaneously grown 
H1975 tumors was determined 
at the indicated time points under 
treatment with vehicle, ZD6474 
alone, PD0325901 (12 mg/kg) 
alone, or a combination of 
PD0325901 plus ZD6474. (C and 
D) Impact of ZD6474 treatment on 
feed-forward activation of insulin 
receptor signaling was determined 
(C) by IHC and (D) by Western 
blots using the indicated antibod-
ies. Scale bar: 200 μm.
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were ordered from Sigma-Aldrich. Replication-incompetent lentiviruses 
were produced from pLKO.1 vector (www.broad.mit.edu/genome_bio/trc/) 
by cotransfection with Δ8.9 and pMGD2 in HEK 293T cells (www.broadins-
titute.org/rnai/trc/lib) using TRANS-IT. Cells were transduced in the pres-
ence of polybrene. After transduction, cells were selected with puromycin.
Lentiviral RNAi, retroviral expression, and stable transduction. The VEGFR2 
V916M mutation was introduced into H1975 cells using a pBABE vector by 
site-directed mutagenesis. Replication-incompetent retroviruses were pro-
duced by cotransfection with the pCL ampho plasmid in HEK 293T cells 
(Orbigen) using TRANS-IT (Mirus). Hairpins targeting the different genes 
Figure 5
Combined inhibition of VEGFR2 and ERK signaling induces tumor shrinkage in an orthotopic KrasVal12-driven murine lung lung cancer model 
(RasLo). (A–C) KrasVal12-driven orthotopic murine lung tumors were induced; mice with Luc-positive tumors were treated, and BL imaging 
was performed on day 0 (before treatment) and at the indicated time points after treatment. Mice were treated with vehicle, ZD6474 alone, 
PD0325901 (12 mg/kg) alone, or a combination of PD0325901 plus ZD6474. The scale bar represents the luciferase activity in detected counts 
(photons/s/cm2/steradian × 10; red, high; blue, low). Graphs show quantification of change in BLI based on ROI analysis. (D–F) Images show 
representative lungs ex vivo, with macroscopic lung tumors in mice treated with (E) PD0325901 or (F) ZD6474 only.
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alone. Avastin treatment was given i.p. (twice a week, 5 mg/kg). Tumor size 
was monitored by measuring perpendicular diameters. Tumor volumes 
were calculated by determination of the largest diameter and its perpendic-
ular according to the following equation: tumor volume = a × (b2/2), where a 
represents the largest diameter and b represents the perpendicular diameter.
The RasLO construct is under the β-actin promoter followed by a STOP 
codon flanked by LoxP sites. Human mutated KrasVal12 and a fusion mol-
ecule consisting of ovalbumin, S-tag, and luciferase are expressed after 
excision of the STOP codon by Cre-recombinase encoded in adenoVirus. 
Tumor formation was then noninvasively monitored by BLI (Biospace). 
In order to induce tumor growth specifically in the lung, 107 PFUs of ade-
no-Cre were applied intranasally in RasLO genotyped positive mice between 
6 to 8 weeks old that had been previously anesthetized with ketamine.
Tumor samples and immunohistochemistry. All tumor samples were received 
from the CIO Biobank at the Institute of Pathology, University of Bonn, 
Bonn, Germany. All tumors were clinically and pathologically identified as 
being the primary and only neoplastic lesion and classified according to 
WHO guidelines. Briefly, 3-μm-thick sections of FFPE tumors were dep-
araffinized, and antigen retrieval was performed by boiling the section in 
citrate buffer at pH 6 or EDTA at pH 9 for 20 minuets. Primary antibodies 
used were as follows: VEGF (sc-152, 1:100, pH 6, Santa Cruz Biotechnology 
Inc.), VEGF (bevacizumab, 1:100, pH 6, Roche; secondary anti-human IgG-
FITC, Dako), CD31 (SZ31, 1:50, pH 6, Dianova), VEGFR2 (no. 2479, 1:200, 
pH 9, Cell Signaling Technology), Ki67 (mib-1, 1:100, pH 6, Thermo Sci-
entific), pERK (no. 4376, 1:50, pH 6, Cell Signaling Technology), pMAPK 
(no. 4631, 1:50, pH 6, Cell Signaling Technology), IRS-1 (ab40777, 1:50, 
pH 6, Abcam), VEGF:VEGFR 2 (GV39M, 1:2, culture supernatant) (16), 
and HIF-1α (1:300, Cell Signaling Technology). Corresponding secondary 
antibody detection kits for reduced background on murine tissue were 
used (Histofine Simple Stain Mouse MAX PO, medac) and stained on an 
automated stainer (LabVision Autostainer 480S, Thermo Scientific). VEGF 
and VEGFR2 immunofluorescence was performed using the same primary 
antibodies and secondary antibodies. Staining intensities were individually 
evaluated by 3 independent observers, using a 4-tier scoring system. Statis-
tical analysis was performed using a Fisher’s exact test.
Statistics. Fisher’s exact tests were performed using R version 2.7.1 (http://
www.r-project.org/). A level of significance of P < 0.05 was chosen. Data are 
presented as mean ± SD in all figure panels in which error bars are shown.
Study approval. All animal procedures were in accordance with the Ger-
man laws for animal protection and were approved by the local animal care 
committee and local governmental authorities (Recklinghausen, Germany).
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Western blotting. Western blotting was performed using the following anti-
bodies: β-actin (clone C4) (MPBiomedicals LLC); pAKT (S473), AKT, pS6K, 
S6K, IRS-1, pERK, ERK, pVEGFR2, VEGFR2, VEGFR1, and pFoxO3a (all 
from Cell Signaling Technology); and anti-rabbit-HRP and anti-mouse-
HRP antibodies (all from Millipore).
Immunoprecipitation. Protein A/G PLUS-Agarose Beads (Santa Cruz Bio-
technology Inc.) were washed twice in PBS and resuspended in 500 μl of lysis 
buffer. Anti-phosphotyrosine antibody (clone 4G10) (Millipore), diluted 1:50, 
was added and incubated overnight in a rotating chamber at 4°C. Tubes were 
centrifuged at 1,000 g for 1 minute and washed 3 times in ice-cold PBS. 500 μg 
of cell lysate was added, and the volume of the tube was filled up to 1 ml with 
lysis buffer. Tubes were incubated in a similar manner and were centrifuged 
and washed as described above. After removing the supernatant, beads were 
resuspended in ×4 NuPage LDS buffer (Invitrogen) and heated at 80°C for 
10 minutes. Supernatant was carefully pipetted and loaded in a gel for West-
ern blotting. pVEGFR2 was used as the primary antibody.
ELISA assay. Cells were plated in 6-well plates and incubated for 24 hours 
in starving media. Cells were then stimulated with 40 ng VEGF-A 165 
either alone or after pretreatment with the VEGFR2 inhibitor ZD6474 
(1 μM) or with rapamycin (100 nM) for 4 hours. Secretion of VEGF into 
cell culture supernatants was measured with the VEGF Human ELISA Kit 
from Tebu-Bio GmbH (catalog no. ELH-VEGF-001) according to the man-
ufacturer’s instructions.
Flow cytometry. Cells were plated in 6-well plates and incubated for 24 hours 
in starving media. Cells were then either treated with DMSO or stimu-
lated with 40 ng VEGF-A 165 alone or after pretreatment with ZD6474 
(0.5 and 1 μM) for 4 hours. The incorporated BrdU was stained with 
specific anti-BrdU fluorescent antibodies. All protocols were performed 
according to instructions for the BrdU Flow Kit from BD Pharmingen (cat-
alog no. 559619). The levels of cell-associated BrdU were then measured on 
a Gallios Flow Cytometer from Beckman Coulter. Results were calculated 
using Gallios FACS software.
PET and BLI. Nude mice bearing macroscopic H1975WT tumors were 
treated daily with an oral gavage of 75 mg/kg ZD6474 and investigated 
using a FOCUS microPET Scanner (Concord Microsystems Inc.). [18F]
FLT and [11C]MET were synthesized as described previously (22). No-car-
rier-added [18F]FLT and [11C]MET were administered i.v. (tail vein) into 
experimental animals with a dose of 200 μCi per mouse and 400 μCi per 
mouse, respectively. [18F]FLT PET and [11C]MET PET imaging were per-
formed 60 minutes and 20 minutes after injection, respectively. Evaluation 
of data was based on a ROI analysis of the entire tumor using in-house 
software (VINCI). For data analysis, we used the maximal voxel radioac-
tivity within the tumors. The mediastinum was chosen as a reference for 
determination of uptake ratio, since we observed constant uptake for [18F]
FLT and [11C]MET in this region. The heart was used as a reference for 
calculation of the [15O]H2O. All data were decay corrected.
Analysis of luciferase gene expression was performed using an optical 
imaging system (Biospace). For bioluminescence detection, mice were 
injected intraperitoneally with d-luciferin (4 mg per animal in 200 μl PBS), 
and images were acquired 10 minutes after luciferin injection. Evaluation 
of data was performed using ROI analysis of BLI images to determine max-
imum values in photons. Data were background subtracted.
Mouse models. All animal procedures were approved by the local animal pro-
tection committee and the local authorities. For each tumor xenograft, 5 × 106 
cells from individual cell lines suspended in plain RPMI were injected sub-
cutaneously into male nude mice. Mice (with established tumors [70 mm3] 
or 1 day after tumor cell inoculation) were treated daily by oral gavage of 
ZD6474 (75 mg/kg, dissolved in sterile, deionized water with 1% Tween 80), 
PD0325901 (12 mg/kg, dissolved in propylene glycol/water [1:1]), the com-
bination of ZD6474 (75 mg/kg) and PD0325901 (12 mg/kg), or vehicle 
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